The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Lipid Nanoparticles for the Posterior Eye Segment
Open accessAbstract
This review highlights the application of lipid nanoparticles (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, or Lipid Drug Conjugates) as effective drug carriers for pathologies affecting the posterior ocular segment. Eye anatomy and the most relevant diseases affecting the posterior segment will be summarized. Moreover, preparation methods and different types and subtypes of lipid nanoparticles will also be reviewed. Lipid nanoparticles used as carriers to deliver drugs to the posterior eye segment as well as their administration routes, pharmaceutical forms and ocular distribution will be discussed emphasizing the different targeting strategies most recently employed for ocular drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Barriers to ocular drug penetration: (a) the tear film is composed of three layers, the lipid layer, the aqueous layer and the mucin layer; (b) the corneal layer is formed by epithelium, Bowman’s membrane, stroma, Descemet’s membrane and endothelium; (c) the conjunctival barrier is vascularized; (d) the blood–aqueous barrier starts on the stroma of ciliary body and is composed by the basement membrane, pigmented cells, nonpigmented cells and delimited by the basement membrane; (e) the blood–retinal barrier is formed by the retinal ganglion cells, amacrine cells, bipolar cells, horizontal cells, both types of photoreceptors, retinal pigment epithelium (RPE) and the Bowman’s membrane. Adapted from [3,14,15], Sánchez-López, E., 2017; Farid, R.M., 2017; and Keeling, E., 2018.](https://figures.cochat.ai/paper-figures/81f1ec683a194953bac4868af7024759/lipid-nanoparticles-for-the-posterior-eye-segment-figure-1.jpg)
![Figure 2 Anatomy of the posterior segment of the eye. Adapted from [24,25] Akbar, S., 2017 and Bharali, P., 2015.](https://figures.cochat.ai/paper-figures/aaa59bfb5f1b44a89d521436564b298e/lipid-nanoparticles-for-the-posterior-eye-segment-figure-2.jpg)
![Figure 3 Representation of the different delivery routes for ocular administration [31,32]. Next to each administration, needle and injection technique are summarized. Adapted from [23,33,34,35,36,37,38,39], Varela-Fernandez, R., 2020; Doshi, R., 2011; Moshfeghi, D.M., 2002; Yïu, G., 2020; El Raves, E.N., 2013; Do, J.L., 2020; Pakravan, M., 2017; Davis, J.L., 2019.](https://figures.cochat.ai/paper-figures/b061b71884594be8a35a218a7f68fbc2/lipid-nanoparticles-for-the-posterior-eye-segment-figure-3.jpg)
![Figure 4 Three models of SLN drug incorporation: (a) homogeneous matrix model, (b) drug-enriched shell model, (c) drug enriched core model. Red color indicates the active compound encapsulated, yellow and grey color refer to lipid phases with and without dispersed drug, respectively. Adapted from [63], Müller, R. H., 2000.](https://figures.cochat.ai/paper-figures/8d1e7d9c9f08433cac2cdbb6456e23bb/lipid-nanoparticles-for-the-posterior-eye-segment-figure-4.jpg)
![Figure 5 Representation of the drug expulsion during storage of SLNs and three types of NLC: type-I structurally different lipids, type-II amorphous lipids and type-III liquid lipid included in solid matrix. Red color indicates the active compound. Adapted from [68,69], Müller, R.H., 2002; Narvekar, M., 2014.](https://figures.cochat.ai/paper-figures/7098428b8be3480c93c3636cfea6b382/lipid-nanoparticles-for-the-posterior-eye-segment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [88]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhu, Y., & Sheng, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119688 · Cited by 38
RetractedLiu, Z., Jiao, Z., Luo, R., & Fu, J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102731 · Cited by 12
RetractedDanaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Nanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Research works printed but not linked: 1
- Pawan, 2018, A review on impact of nanomicelle for ocular drug delivery system, Int. J. Pharm. Sci. Res., 9, 1397
Cited by
Akbari, J., Saeedi, M., Ahmadi, F., Hashemi, S. M. H., Babaei, A., Yaddollahi, S., Rostamkalaei, S. S., Asare-Addo, K., & Nokhodchi, A. (2022) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2022.2084554 · Cited by 181
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds
Razavi, M. S., Ebrahimnejad, P., Fatahi, Y., D’Emanuele, A., & Dinarvand, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.850757 · Cited by 92
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 96
Wu, Y., Li, X., Fu, X., Huang, X., Zhang, S., Zhao, N., Ma, X., Saiding, Q., Yang, M., Tao, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202403399 · Cited by 105
Metadata
- Authors
- Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E.
- Affiliations
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
- Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona (ES)
- Industrial Biotechnology Program, University of Tiradentes (UNIT), Av. Murilo Dantas 300, Aracaju 49032-490, Brazil
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- University of Minho (PT)
- Corresponding author
- Souto, Eliana B.
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-12-31
- Volume
- 14
- Issue
- 1
- Pages
- 90
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8779178
- OpenAlex
- W4205965704
- Cited by
- 76
- References
- 160
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 22 · 2023: 20 · 2022: 10
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
- Funders
- Fundação para a Ciência e a Tecnologia (UIDB/04469/2020, COMPETE, PT2020, UIDB/04469)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, lipid-drug conjugates, ocular drug delivery, ocular distribution, eye anatomy, posterior segment diseases, nanoparticle synthesis, route of administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Nanoparticles for the Posterior Eye Segment. https://app.cochat.ai/papers/10.3390/pharmaceutics14010090
- The paper
- Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021). Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14010090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.